Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 121 people enrolled
- Started
- 1 Sept 2022
- Ended
- 1 Dec 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Women Enrolled
- Newborns of Female Study Participants
- Record updated
- 7 October 2026
Who can take part
- Age
- 1 hour to 35 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Other criteria
- Inclusion:
- Women in Ribeirao Preto who receive maternity care through the Hospital Das Clinicas, University of São Paulo and the Mater Hospital
- enrollment in prenatal care before 23 weeks gestation; Exclusion:
- late enrollment in prenatal care, after 23 weeks gestation
- known major fetal anomalies or demise
- planned termination of pregnancy
- intention of the patient to deliver at a non-study hospital
- referral for high risk prenatal care
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objectives of the protocol are to determine if a structured cognitive-behavioral interventional counseling of pregnant women can limit acquisition of human cytomegalovirus (HCMV) during pregnancy that we believe, will in turn decrease the incidence of congenital HCMV infections in this highly seroimmune population. Previously, investigators have demonstrated the success of a similar approach in pregnant women without previous evidence of HCMV infection (non-immune women) but to date, there is no evidence that such an approach will alter the incidence of congenital HCMV infections in seroimmune women. This protocol will take advantage of recently derived data in this maternal population that has identified sources HCMV exposure in women in this population and thus provided new insight into targeted counseling interventions that could limit maternal acquisition of HCMV. The primary endpoints of this study will be a 50% reduction in the overall incidence of congenital HCMV infections in this maternal population with secondary endpoints being efficient uptake of behavioral recommendations and modifications of simple hygiene behaviors that have previously been shown to decrease exposure and acquisition of HCMV.
The 2 groups in the trial
- women enrolledTreatment being tested
pregnant women enrolled in trial
- newborns of female study participantsOther group
newborns will be tested to determine if virus is present.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 7 October 2026